A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Oriol MitjàMarc Corbacho-MonnéMaria UbalsAndrea AlemanyClara SuñerCristian TebéAurelio TobiasJudith PeñafielEster BallanaCarla A PérezPol AdmellaNúria Riera-MartíPep LaporteJordi MitjàMireia CluaLaia BertranMaria SarquellaSergi GavilánJordi AraJosep M ArgimonGabriel CuatrecasasPaz CañadasAleix Elizalde-TorrentRobert FabregatMagí FarréAnna ForcadaGemma Flores-MateoCristina LópezEsteve MuntadaNúria NadalSilvia NarejosAroa NietoNuria PratJordi PuigCarles QuiñonesFerran Ramírez-ViaplanaJuliana Reyes-UrueñaEva Riveira-MuñozLidia RuizSergi SanzAlexis SentísAlba SierraCésar VelascoRosa M Vivanco-HidalgoJuani ZamoraJordi CasabonaMartí Vall-MayansCamila González-BeirasBonaventura Clotetnull nullPublished in: The New England journal of medicine (2020)
Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.).